Redefining
Cancer
Treatment
Redefining
Cancer
Treatment
Melatonin supplements are widely available in the UK with prices ranging from £5 to £30 depending on dosage, formulation, and brand.
Click 
Melatonin, a hormone produced by the pineal gland, has been extensively studied for its potential anti-cancer properties. Here’s a comprehensive overview of melatonin’s role in cancer treatment, focusing on its mechanisms, benefits, and current research:
Melatonin is known for its antioxidant, anti-inflammatory, and immune-modulating effects, which contribute to its potential as an anticancer agent. Epidemiological and experimental studies have shown that melatonin can inhibit the growth of various types of cancer cells both in vitro and in vivo129.
Melatonin exerts its anti-cancer effects through several mechanisms:
Apoptosis Induction: Melatonin promotes apoptosis (programmed cell death) in cancer cells, which helps in reducing tumour size and progression15.
Antioxidant Activity: It scavenges reactive oxygen species (ROS), protecting cells from oxidative damage and potentially reducing cancer initiation9.
Anti-Angiogenic Effects: Melatonin inhibits angiogenesis, the formation of new blood vessels that tumours need for growth and metastasis16.
Modulation of Metabolic Pathways: Melatonin affects cancer cell metabolism by regulating glucose uptake and aerobic glycolysis, which are crucial for cancer cell proliferation57.
Immune System Modulation: It enhances the immune response against cancer cells by modulating T cells and other immune components10.
Melatonin has been studied for its effects on various cancers, including:
Breast Cancer: Melatonin inhibits breast cancer cell growth, particularly in estrogen receptor-positive tumors, by modulating estrogen signaling pathways111.
Prostate Cancer: It reduces glucose uptake in prostate cancer cells, affecting their metabolism and proliferation5.
Colorectal Cancer: Melatonin induces apoptosis and autophagy in colorectal cancer cells, contributing to tumour suppression2.
Other Cancers: Melatonin has shown potential in treating gastric, lung, and liver cancers by inhibiting cell growth and inducing apoptosis16.
Numerous clinical trials have investigated melatonin’s role in cancer treatment. While results are promising, with improvements in survival rates and reduced chemotherapy side effects, more standardised and large-scale trials are needed to confirm its efficacy34. Melatonin is often used as an adjuvant therapy to enhance the effects of conventional treatments like chemotherapy and radiotherapy46.
Melatonin’s anti-cancer properties make it a promising adjunctive therapy for various types of cancer. Its ability to modulate metabolic pathways, induce apoptosis, and enhance immune responses against cancer cells underscores its potential in cancer management. Further research is necessary to fully explore its therapeutic potential and optimise its use in clinical settings.
The recommended dosage of melatonin for its anti-cancer properties varies depending on the context and specific application. In clinical trials, melatonin has been used in doses ranging from 3 mg to 40 mg per day.
Clinical Trials for Cancer: Doses of 10 to 20 mg per day are commonly used in clinical trials, with some studies indicating that 20 mg per day can improve outcomes by reducing chemotherapy toxicity and enhancing survival rates in breast cancer patients34.
Higher Doses: Some studies suggest that doses up to 40 mg per day may be effective when combined with other treatments like immunotherapy4.
Animal Studies: Equivalent human doses (HEDs) derived from animal studies range from 1 mg to 486 mg per day, though these are not directly applicable to human treatment without further research3.
It’s important to note that while melatonin is generally considered safe, the optimal dosage for cancer treatment remains under investigation, and more research is needed to establish standardised dosing guidelines.
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Melatonin is generally considered safe, but it can cause several side effects, especially when taken in high doses. Here are some common side effects associated with melatonin use:
Headaches: One of the most commonly reported side effects35.
Drowsiness: Can cause daytime sleepiness, especially in older adults35.
Changes in Sleep Patterns: May lead to trouble sleeping or vivid dreams/nightmares35.
Stomach Issues: Includes nausea, stomach cramps, and diarrhea245.
Mood Changes: Brief bouts of depression, anxiety, and irritability45.
Cardiovascular Effects: Can increase blood pressure and heart rate, especially in those already with hypertension23.
Interactions with Medications: May interact with blood thinners, nifedipine, and other medications35.
In rare cases, melatonin can exacerbate conditions like myasthenia gravis and may cause facial swelling in some individuals3. It’s important to consult a healthcare provider before starting melatonin, especially if you have underlying health conditions or are taking other medications.
There have been a few studies on melatonin as part of combination therapies for cancer treatment.
Here are some key findings:
Enhanced Efficacy: Melatonin has been shown to enhance the effects of chemotherapy by improving survival rates and reducing chemotherapy-induced side effects such as asthenia, leucopoenia, nausea, vomiting, and hypotension345.
Synergistic Effects: When combined with chemotherapy, melatonin can improve outcomes like complete and partial remission rates and reduce mortality34.
Radioprotective Effects: Melatonin’s antioxidant properties provide radioprotective effects, helping protect normal tissues from radiation damage1.
Enhanced Survival: Studies suggest that melatonin can improve survival when used alongside radiotherapy by reducing side effects and enhancing therapeutic efficacy34.
Immune Modulation: Melatonin can modulate immune responses, potentially enhancing the effectiveness of immunotherapies by activating natural killer cells and modulating regulatory T-cells1.
Interleukin-2 (IL-2): Melatonin combined with IL-2 has shown improved outcomes in cancer patients by stimulating IL-2 production, which enhances immune responses against cancer cells1.
Other Anticancer Drugs: Melatonin can enhance the effects of drugs like doxorubicin by activating apoptosis pathways and improving drug efficacy4.
Overall, melatonin’s role in combination therapies is promising, as it can enhance treatment efficacy and reduce side effects associated with conventional cancer treatments.
US National Library of Medicine research on Melatonin
Europe PMC research on Melatonin
Pubmed research on Melatonin
The impact of melatonin on quality of life (QoL) in cancer patients varies depending on the study and specific outcomes measured.
Here are some key findings:
Improvement in Sleep and Fatigue: Melatonin has been shown to improve sleep quality and reduce fatigue in some studies. For example, a study involving metastatic breast cancer patients found that melatonin improved sleep fragmentation, subjective sleep quality, and fatigue severity17.
Mixed Effects on Overall QoL: Systematic reviews and meta-analyses have reported mixed results regarding melatonin’s impact on overall QoL. Some studies found no significant improvement in QoL, sleep quality, or fatigue23, while others suggested benefits in specific aspects like reducing stomatitis rate and easing depression3.
Enhanced Cognitive and Social Functioning: In some cases, melatonin has been associated with improved cognitive and social functioning scales, contributing to better QoL16.
Long-Term Use: Long-term use of melatonin (e.g., 3 years) in non-metastatic breast cancer patients has been linked to increased QoL6.
Overall, while melatonin may offer some benefits in improving sleep and reducing fatigue, its impact on overall QoL is variable and requires further research to fully understand its effects across different cancer types and treatment contexts.
We’ve done our best to include as much information as possible for this supplement.
If you have any other questions, please send us a message or join our Skool Group and ask our knowledgeable and friendly community.
Melatonin is readily available over the counter in the UK, EU, USA, Australia, and NZ, typically classified as a dietary supplement. Regulations regarding dosage and permitted health claims may vary by country.
While specific patient demographics have not been extensively detailed as the primary focus for melatonin use in cancer treatment, certain groups may benefit more from its application based on existing research:
Advanced Cancer Patients: Melatonin has shown benefits in patients with advanced solid tumours, particularly in improving survival rates and reducing chemotherapy side effects26.
Poor Prognosis Groups: In prostate cancer, melatonin significantly improved survival in patients with poor prognosis, suggesting its potential in high-risk or advanced cases38.
Older Adults: Given its generally safe profile, melatonin might be particularly beneficial for older adults who may experience more severe side effects from conventional treatments.
Patients with Disrupted Circadian Rhythms: Individuals with disrupted sleep patterns, such as those working night shifts, may benefit from melatonin due to its role in regulating circadian rhythms and potentially reducing cancer risk1.
However, more research is needed to determine specific demographic groups that would most benefit from melatonin therapy in cancer treatment. Factors such as age, cancer type, and overall health status should be considered when evaluating the suitability of melatonin for individual patients.
Several resistance mechanisms have been identified that could affect the positive outcomes of melatonin in cancer treatment:
Multidrug Resistance (MDR) Transporters: Cancer cells often develop resistance to chemotherapy by overexpressing ATP-binding cassette (ABC) transporters like ABCG2/BCRP, which efflux drugs out of cells, reducing their intracellular concentration and efficacy. Melatonin has been shown to downregulate ABCG2/BCRP expression, potentially overcoming this resistance by increasing intracellular drug accumulation2.
Epithelial-to-Mesenchymal Transition (EMT): EMT is a process that enhances cancer cell migration and invasion, contributing to metastasis and resistance to therapies. Melatonin has antimetastatic effects by inhibiting EMT, but if cancer cells develop mechanisms to bypass or counteract this inhibition, it could limit melatonin’s effectiveness1.
Circadian Rhythm Disruptions: Melatonin’s efficacy is linked to its role in regulating circadian rhythms. Disruptions in these rhythms, common in cancer patients, might affect melatonin’s therapeutic potential by altering its natural production and action1.
Genetic Variations: Variations in genes related to melatonin receptors or signalling pathways could influence how well cancer cells respond to melatonin. For instance, differences in the expression or function of melatonin receptors (MT1 and MT2) might affect the drug’s ability to induce apoptosis or inhibit cell proliferation1.
Epigenetic Modifications: While melatonin can modulate epigenetic markers, cancer cells might develop resistance by altering these modifications in ways that counteract melatonin’s effects. For example, changes in DNA methylation or histone acetylation could reduce the effectiveness of melatonin in regulating gene expression2.
Understanding these resistance mechanisms is crucial for optimising melatonin’s use in cancer therapy and developing strategies to overcome them.
Studies have shown that melatonin inhibits the growth and metastasis of lung cancer cells both in vitro and in vivo.
In Vitro Studies: Melatonin has been shown to inhibit cell proliferation and induce apoptosis in lung cancer cell lines such as A549 and H1299, demonstrating its potential to reduce cancer cell growth14.
In Vivo Studies: Animal models, including those with lung cancer, have demonstrated that melatonin can reduce tumor growth and metastasis. For example, melatonin has been found to decrease metastatic volume in mice with Lewis lung carcinoma1.
These findings support the idea that melatonin has anti-cancer effects against lung cancer, both in laboratory settings and in animal models.
A search on ClinicalTrials.gov reveals numerous ongoing clinical trials investigating the role of melatonin in cancer treatment.
Currently, there is limited direct evidence linking specific genetic markers to the efficacy of melatonin in cancer treatment.
However, some studies suggest potential associations:
PER3 Gene: Research indicates that polymorphisms in the PER3 gene, which is involved in circadian rhythm regulation, may influence melatonin production and its diurnal pattern. This could indirectly affect its efficacy in cancer treatment, as circadian rhythm disruptions are linked to cancer incidence and prognosis2.
Melatonin Receptors: The presence and expression of melatonin receptors, such as MT1 and MT2, play a crucial role in mediating melatonin’s effects on cancer cells. For example, MT1 receptor expression is important for melatonin’s oncostatic actions in ER-positive breast cancer cells16. Variations in these receptors could potentially influence the efficacy of melatonin.
Epigenetic Modifications: Melatonin can alter DNA methylation patterns, affecting gene expression in cancer cells. This epigenetic modulation is a promising area for understanding how melatonin impacts cancer treatment outcomes3. However, specific genetic markers related to these epigenetic changes have not been widely identified.
While genetic factors like PER3 polymorphisms and melatonin receptor expression may influence melatonin’s efficacy, more research is needed to identify specific genetic markers that predict its effectiveness in cancer treatment.
Pterostilbene benefits include antioxidant and anti-inflammatory effects, with potential therapeutic applications in cancer, neuroprotection, and cardiovascular health. Learn more about
Website designed in collaboration with Simon Lown for Metabolic Therapy Ltd
Apoptosis, or programmed cell death, is a natural process where cells self-destruct when they are damaged or no longer needed. This is crucial for maintaining healthy tissues and preventing diseases like cancer.
Drugs and supplements that induce apoptosis help eliminate cancerous cells by triggering this self-destruct mechanism, ensuring that harmful cells are removed without damaging surrounding healthy tissue.
Understanding and harnessing apoptosis is vital in the fight against cancer, as it targets the root cause of the disease at the cellular level.
Cell proliferation is the process by which cells grow and divide to produce more cells. While this is essential for growth and healing, uncontrolled cell proliferation can lead to cancer.
Drugs and supplements that inhibit cell proliferation help prevent the rapid multiplication of cancerous cells, slowing down or stopping the progression of the disease.
By targeting the mechanisms that drive cell division, these treatments play a vital role in controlling and potentially eradicating cancer.
Cancer cells often hijack specific biological pathways to grow and spread. Drugs and supplements that target these pathways can disrupt the cancer cell’s ability to survive and multiply.
By focusing on the unique mechanisms that cancer cells use, these treatments can be more effective and cause fewer side effects compared to traditional therapies.
Targeting specific pathways is a key strategy in precision medicine, offering a tailored approach to combat cancer at its core.
Angiogenesis is the process by which new blood vessels form, supplying nutrients and oxygen to tissues. Cancer cells exploit this process to fuel their growth and spread.
Drugs and supplements that inhibit angiogenesis can effectively starve cancer cells by blocking the formation of these new blood vessels.
By cutting off the supply lines that tumors rely on, angiogenesis inhibitors play a crucial role in controlling and potentially shrinking cancerous growths.
Immunotherapy harnesses the power of the body’s immune system to combat cancer. By boosting or restoring the immune system’s natural ability to detect and destroy cancer cells, immunotherapy offers a targeted and effective approach to treatment.
Drugs and supplements that support immunotherapy can enhance the immune response, making it more efficient at identifying and attacking cancer cells.
This innovative approach not only helps in treating cancer but also reduces the risk of recurrence, providing a powerful tool in the fight against this disease.
Inflammation is the body’s natural response to injury or infection, but chronic inflammation can contribute to the development and progression of cancer.
Drugs and supplements with anti-inflammatory properties help reduce inflammation, thereby lowering the risk of cancer and other chronic diseases.
By targeting the inflammatory processes, these treatments can help maintain a healthier cellular environment and prevent the conditions that allow cancer to thrive.
